Servier and Pfizer announce FDA clearance of IND application for UCART19 in Adult Relapsed/Refractory Acute Lymphoblastic Leukemia
All the news from Servier
Pieris Pharmaceuticals and Servier Forge Strategic Immuno-oncology Co-development Alliance